akın öztürk

Mr. akın öztürk


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MGMustafa Gürbüz
Mustafa Gürbüz
YKYasin Kutlu
Yasin Kutlu
EAErman Akkus
Erman Akkus
EKElif Berna Köksoy
Elif Berna Köksoy
NBNaziyet Köse Baytemür
Naziyet Köse Baytemür
ADAhmet Demirkazık
Ahmet Demirkazık

31 March 2025 in Medicina
Verified
Journal Article
Open access
PDF file
ZKZiya KALKAN
Ziya KALKAN
SESenar Ebinc
Senar Ebinc
Murat ArcagokMurat Arcagok
Murat Arcagok
ABAhmet Bilici
Ahmet Bilici
OYOzcan Yildiz
Ozcan Yildiz
MKMuhammet Ali Kaplan
Muhammet Ali Kaplan
Background and Objectives: This study aimed to evaluate the effectiveness of immunotherapy compared to chemotherapy across different treatment lines in patients with pleural mesothelioma. It also sought to identify factors influencing the success of immunotherapy, such as histological subtype, PD-L1 expression, type of asbestos exposure, and metastatic status. Materials and Methods: A retrospective analysis was conducted with 60 patients diagnosed with pleural mesothelioma. Data on age, gender, histological subtype, and asbestos exposure were collected for all patients and PD-L1 expression was assessed in a subset of patients. Patients received either chemotherapy or immunotherapy as first-, second-, and third-line treatments, and progression-free survival (PFS) and treatment responses were evaluated. Results: Among the 60 patients, 35 (58.3%) were male and the median age was 59 years. The majority (71.7%) had epithelioid histology and 28.3% had distant metastases. Asbestos exposure was documented in 65% of the cases. PD-L1 expression of ≥1% was found in 13 of 17 patients tested. First-line treatments included immunotherapy for 11 patients and chemotherapy for the others, with immunotherapy achieving median PFS of 9 months versus 6 months for chemotherapy, although the difference was not statistically significant. In third-line treatments, immunotherapy significantly outperformed chemotherapy with median PFS of 6 months compared to 3 months (p = 0.048). Absence of metastasis and prior asbestos exposure in an endemic region were linked to better immunotherapy outcomes. Conclusion: Immunotherapy shows increased efficacy in later treatment lines for pleural mesothelioma, especially for patients without metastases or with prior endemic asbestos exposure. Tailored therapeutic strategies should be further explored in prospective studies.

5 April 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
PGPınar Gürsoy
Pınar Gürsoy
ATAli Murat Tatli
Ali Murat Tatli
DEDilek Erdem
Dilek Erdem
EGERDEM GOKER
ERDEM GOKER
EÇEmir Çelik
Emir Çelik
PYPerran Fulden Yumuk
Perran Fulden Yumuk

13 October 2023 in Medicine
Verified
Journal Article
Open access
AÖakın öztürk
akın öztürk
RSRekib Sacaklidir
Rekib Sacaklidir
FUFirat Ulutatar
Firat Ulutatar
This study aimed to examine the frequency of fibromyalgia (FM) in patients with lung cancer and evaluate its effect on patients’ pain, sleep quality, fatigue, and quality of life parameters. The study was designed as a prospective cross-sectional and a total of 116 lung cancer patients were included. FM classification was made according to the 2016 ACR criteria. All patients were evaluated using a visual analog scale, fibromyalgia impact questionnaire, multidimensional assessment of fatigue, EuroQol 5D scale, Jenkins sleep scale, and Beck depression inventory. Patients were divided into FM-positive and negative groups according to the presence of FM. Demographic and clinical parameters were investigated between the groups. FM was detected in 14 (12.2%) patients. The mean age of the patients was 62.2 ± 8.4 years. There was a male predominance in 93 (80.2%) patients. No statistical difference was found between the groups in terms of body mass index, age, symptom duration, chemotherapy, and radiotherapy history. A statistically significant difference was found between FM positive and negative groups in FIQ, multidimensional assessment of fatigue, JSS, EQ-5D, visual analog scale, and Beck depression inventory scores. FM is seen more frequently in patients with lung cancer and has a negative effect on sleep, quality of life, fatigue, and mental functions. We think that physicians should not ignore the presence of FM when treating patients diagnosed with lung cancer.

11 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ZKZiya Kalkan
Ziya Kalkan
SESenar Ebinc
Senar Ebinc
Murat ArcagokMurat Arcagok
Murat Arcagok
ABAhmet Bilici
Ahmet Bilici
OYOzcan Yildiz
Ozcan Yildiz
MKMuhammet Ali Kaplan
Muhammet Ali Kaplan
Background and Objectives: This study aimed to evaluate the effectiveness of immunotherapy compared to chemotherapy across different treatment lines in patients with malignant pleural mesothelioma. It also sought to identify factors influencing the success of immunotherapy, such as histological subtype, PD-L1 expression, type of asbestos exposure, and metastatic status. Materials and Methods: A retrospective analysis was conducted with 60 patients diagnosed with malignant pleural mesothelioma. Data on age, gender, histological subtype, and asbestos exposure were collected for all patients and PD-L1 expression was assessed in a subset of patients. Patients received either chemotherapy or immunotherapy as first-, second-, and third-line treatments, and progression-free survival (PFS) and treatment responses were evaluated. Results: Among the 60 patients, 35 (58.3%) were male and the median age was 59 years. The majority (71.7%) had epithelioid histology and 28.3% had distant metastases. Asbestos exposure was documented in 65% of the cases. PD-L1 expression of ≥1% was found in 13 of 17 patients tested. First-line treatments included immunotherapy for 11 patients and chemotherapy for the others, with immunotherapy achieving median PFS of 9 months versus 6 months for chemotherapy, although the difference was not statistically significant. In third-line treatments, immunotherapy significantly outperformed chemotherapy with median PFS of 6 months compared to 3 months (p=0.048). Absence of metastasis and prior asbestos exposure in an endemic region were linked to better immunotherapy outcomes. Conclusion: Immunotherapy shows increased efficacy in later treatment lines for malignant pleural mesothelioma, especially for patients without metastases or with prior endemic asbestos exposure. Tailored therapeutic strategies should be further explored in prospective studies.

24 May 2024 in Medicine
Verified
Journal Article
Open access
SKSaadettin Kilickap
Saadettin Kilickap
AÖakın öztürk
akın öztürk
NKNuri Karadurmus
Nuri Karadurmus
TKTaner Korkmaz
Taner Korkmaz
PYPerran Fulden Yumuk
Perran Fulden Yumuk
LGLung Sub-Group Study of the Turkish Oncology Group
Lung Sub-Group Study of the Turkish Oncology Group
To evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive screening study evaluated demographic, clinical, and radiological imaging features, and treatment approaches in patients treated between 2013-2017. Totally 367 patients (54.8% males, median age at diagnosis 54 years) were included. Of them, 45.4% were smokers, and 8.7% had a family history of lung cancer. On radiological findings, 55.9% of the tumors were located peripherally, 7.7% of the patients had cavitary lesions, and 42.9% presented with pleural effusion. Pleural effusion was higher in nonsmokers than in smokers (37.3% vs. 25.3%, P = .018). About 47.4% of cases developed distant metastases during treatment, most frequently to the brain (26.2%). Chemotherapy was the first line treatment in 55.0%. Objective response rate was 61.9% (complete response: 7.6%; partial response: 54.2%). The highest complete and partial response rates were observed in patients who received crizotinib as the 2nd line treatment. The median progression-free survival was 14 months (standard error: 1.4, 95% confidence interval: 11.2–16.8 months). Crizotinib treatment lines yielded similar progression-free survival (P = .078). The most frequent treatment-related adverse event was fatigue (14.7%). Adrenal gland metastasis was significantly higher in males and smokers, and pleural involvement and effusion were significantly higher in nonsmokers—a novel finding that has not been reported previously. The radiological and histological characteristics were consistent with the literature data, but several differences in clinical characteristics might be related to population characteristics.